Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NEKTAR THERAPEUTICS reported revenue of $55M, down 43.9% year over year. Operating margin was -253.7% and net margin -297.1%, on a free-cash-flow margin of -377.8% with capital expenditure at 0.3% of revenue. Every figure is computed directly from NKTR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $55M | -253.7% | -297.1% |
| FY2024 | $98M | -106.9% | -120.9% |
| FY2023 | $90M | -292.6% | -306.3% |
| FY2022 | $92M | -408.6% | -400.0% |
| FY2021 | $102M | -437.8% | -514.0% |
How does NKTR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.